cyad-101
Cell therapyexperimental
Clinical trial activity
2 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2018 (NCT03692429)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- NKG2-D type II integral membrane proteinImmunity, passive
immunity, passive - NKG2D
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04991948 | Phase 1 | Nov 15, 2021 | Celyad, Merck |
| NCT03692429 | Phase 1 | Oct 1, 2018 | Celyad, Novella Clinical, The Christie NHS Foundation Trust, University of London, University of South Florida |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celyad | For profit | 2 | 2 | 1 | 2018 |
| Merck | For profit | 1 | 0 | 1 | 2021 |
| Novella Clinical | For profit | 1 | 0 | 1 | 2018 |
| The Christie NHS Foundation Trust | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of South Florida | Academic/Hospital | 1 | 0 | 1 | 2018 |
6 organizations
Page 1 / 1